Confounding and Control of Confounding in Nonexperimental Studies of Medications in Patients With CKD

Advances in Chronic Kidney Disease

Volumn 19, Issue 1, 2012, Pages 19-26

  Bradbury, Brian D ^a   Gilbertson, David T ^b   Brookhart, M Alan ^c   Kilpatrick, Ryan D ^d  

^a AMGEN INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^d IL   (United States)

Author keywords

CKD; Confounding; Observational research

Indexed keywords

ANTIANEMIC AGENT; VITAMIN D;

ANEMIA; CAUSAL ATTRIBUTION; CHRONIC KIDNEY DISEASE; CONFOUNDING VARIABLE; DIALYSIS; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; SECONDARY HYPERPARATHYROIDISM; SYSTEMATIC ERROR; TIME; TREATMENT INDICATION;

BIAS (EPIDEMIOLOGY); CONFOUNDING FACTORS (EPIDEMIOLOGY); HUMANS; RENAL INSUFFICIENCY, CHRONIC; RESEARCH DESIGN; TIME FACTORS;

EID: 84857417353     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2012.01.001     Document Type: Review

References (38)

1. Rothman K.J., Greenland S., Lash T.L. Validity in epidemiologic studies. Modern Epidemiology 2008, Lippincott Williams & Wilkins, Philadelphia, PA. 3rd ed. K.J. Rothman, S. Greenland, T.L. Lash (Eds.).
2. Weiss N.S., Dublin S. Accounting for time-dependent covariates whose levels are influenced by exposure status. Epidemiology 1998, 9:436-440.
3. Bradbury B.D., Brookhart M.A., Winkelmayer W.C., et al. Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in non-experimental research: strengths and limitations. Am J Kidney Dis 2009, 54:554-560.
4. Robins J.M. Marginal structural models versus structural nested models as tools for causal inference. Statistical Models in Epidemiology: The Environment and Clinical Trials 1999, 95-134. Springer-Verlag, New York, NY. E. Halloran, D. Berry (Eds.).
5. Joffe M.M. Confounding by indication: the case of calcium channel blockers. Pharmacoepidemiol Drug Saf 2000, 9:37-41.
6. Strom B.L., Melmon K.L. The use of pharmacoepidemiology to study beneficial drug effects. Pharmacoepidemiology 2005, John Wiley & Sons, West Sussex, England. 4th ed. B.L. Strom (Ed.).
7. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
8. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2010, U S Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
9. Brookhart M.A., Patrick A.R., Dormuth C., et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007, 166:348-354.
10. Jackson L.A., Jackson M.L., Nelson J.C., Neuzil K.M., Weiss N.S. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 2006, 35:337-344.
11. Glynn R.J., Schneeweiss S., Wang P.S., Levin R., Avorn J. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol 2006, 59:819-828.
12. Brookhart M.A., Sturmer T., Glynn R.J., Rassen J., Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care 2010, 48:S114-S120.
13. Bailie G.R., Eisele G., Liu L., et al. Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects. Nephrol Dialysis Transplant 2005, 20:1110-1115.
14. Rifkin D.E., Winkelmayer W.C. Medication issues in older individuals with CKD. Adv Chronic Kidney Dis 2010, 17:320-328.
15. Goodkin D.A., Bragg-Gresham J.L., Koenig K.G., et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003, 14:3270-3277.
16. Bradbury B.D., Fissell R., Albert J., et al. Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2007, 2:89-99.
17. Greenland S., Pearl J., Robins J.M. Causal diagrams for epidemiologic research. Epidemiology 1999, 10:37-48.
18. Glymour M.M., Greenland S. Causal Diagrams. Modern Epidemiology 2008, Lippincott Williams & Wilkins, Philadelphia, PA. 3rd ed. K.J. Rothman, S. Greenland, T.L. Lash (Eds.).
19. Greenland S., Neutra R.R. Control of confounding in the assessment of medical technology. Int J Epidemiol 1980, 9:361-367.
20. Pisoni R.L., Gillespie B.W., Dickinson D.M., Chen K., Kutner M.H., Wolfe R.A. The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology. Am J Kidney Dis 2004, 44:S7-S15.
21. Hebert P.L., Geiss L.S., Tierney E.F., Engelgau M.M., Yawn B.P., McBean A.M. Identifying persons with diabetes using Medicare claims data. Am J Med Qual 1999, 14:270-277.
22. Rothman K.J., Greenland S., Lash T.L. Design strategies to improve study accuracy. Modern Epidemiology 2008, Lippincott Williams & Wilkins, Philadelphia, PA. 3rd ed. K.J. Rothman, S. Greenland, T.L. Lash (Eds.).
23. Ray W.A. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003, 158:915-920.
24. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010, 19:858-868.
25. Rosenbaum P.R., Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 79:516-524.
26. Brookhart M.A., Schneeweiss S., Rothman K.J., Glynn R.J., Avorn J., Sturmer T. Variable selection for propensity score models. Am J Epidemiol 2006, 163:1149-1156.
27. Sturmer T., Rothman K.J., Avorn J., Glynn R.J. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution-a simulation study. Am J Epidemiol 2010, 172:843-854.
28. Joffe M.M., Rosenbaum P.R. Invited commentary: propensity scores. Am J Epidemiol 1999, 15:327-333.
29. Kurth T., Walker A.M., Glynn R.J., et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006, 163:262-270.
30. Teng M., Wolf M., Ofsthun M.N., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J AmSoc Nephrol 2005, 16:1115-1125.
31. Tentori F., Albert J., Young E.W., et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dialysis Transplant 2009, 24:963-972.
32. Zhang Y., Thamer M., Cotter D., Kaufmann J., Hernan M. Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Clin J Am Soc Nephrol 2009, 4:638-644.
33. Wang O., Kilpatrick R.D., Critchlow C.W., et al. Relationship between epoetin alfa dose and mortality: findings from a marginal structural model. Clin J Am Soc Nephrol 2010, 5:182-188.
34. Weinhandl E., Gilbertson D.T., Collins A.J. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients. Am J Nephrol 2011, 34:298-308.
35. Angrist J.D., Imbens G.W., Rubin D.B. Identification of causal effects using instrumental variables. J Am Stat Assoc 1996, 81:444-455.
36. Brooks J.M., Irwin C.P., Hunsicker L.G., Flanigan M.J., Chrischilles E.A., Pendergast J.F. Effect of dialysis center profit status on patient survival: a comparison of risk adjustment and instrumental variable approaches. Health Serv Res 2006, 41:2267-2289.
37. Bradbury B.D., Do T., Winkelmayer W.C., Critchlow C.W., Brookhart M.A. Greater epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmacoepidemiol Drug Saf 2009, 18:932-940.
38. Brookhart M.A., Schneeweiss S., Avorn J., Bradbury B.D., Liu J., Winkelmayer W.C. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 2010, 303:857-864.